PITTSBURGH, April 18 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Food and Drug Administration has granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application (ANDA) for Finasteride Tablets USP, 5mg. Finasteride Tablets are the AB-rated generic equivalent of Merck's Proscar^® Tablets, 5 mg, which had annual U.S. sales of approximately $390 million as of December 31, 2005, according to IMS Health.

About Mylan Laboratories

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories, Inc. that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com.

SOURCE Mylan Laboratories Inc.
04/18/2006
CONTACT: Media, Patrick Fitzgerald., or Investors, Kris King, of Mylan
Laboratories Inc., +1-724-514-1800
Web site: http://www.mylan.com
(MYL)